Ann Intern Med

1. XIE Y, Choi T, Al-Aly Z
   Adverse Events After Same-Day COVID-19 and Influenza Vaccination Versus Influenza Vaccination Alone : A Target Trial Emulation.
   Ann Intern Med. 2026 Jun 30. doi: 10.7326/ANNALS-26-00217.
   

   >> Share

   
   
2. 
   Summary for Patients: Adverse Events After Same-Day COVID-19 and Influenza Vaccination Versus Influenza Vaccination Alone.
   Ann Intern Med. 2026 Jun 30. doi: 10.7326/ANNALS-26-00217.
   

   >> Share

   
   

   
   Arch Virol

3. ZHANG X, Liu Y, Yin B, Li C, et al
   Construction of recombinant OPIV3 virus vectoring bivalent Mycoplasma ovipneumoniae adhesins.
   Arch Virol. 2026;171:74.
   

   >> Share

   
   

   
   BMC Pediatr

4. EVARIST MR, Kibonire RA
   Navigating the divide - demographic and individual predictors of low HPV vaccine uptake in rural Uganda.
   BMC Pediatr. 2026 Jul 3. doi: 10.1186/s12887-026-07143.
   

   >> Share

   
   
5. ESKANDARZADEH S, Chavoshzadeh Z, Assadi Fanid M, Ghasemi B, et al
   BCG arthritis in a patient with Severe Combined Immunodeficiency Disorder (SCID): a case report.
   BMC Pediatr. 2026 Apr 22. doi: 10.1186/s12887-026-06866.
   

   >> Share

   
   
6. HANDAPANGODA NP, Ruwansiri LP, Vidanapathirana GU, Liyanapathirana VC, et al
   Prevalence of Streptococcus pneumoniae and Staphylococcus aureus co-colonization in healthy children under five years: a systematic review.
   BMC Pediatr. 2026 Mar 14. doi: 10.1186/s12887-026-06736.
   

   >> Share

   
   
7. FIAWOO M, Halatoko WA, Nikiema C, Guedenon KM, et al
   Epidemiological characteristics of measles in children in Togo from 2020 to 2024: a cross-sectional study.
   BMC Pediatr. 2026;26:120.
   

   >> Share

   
   

   
   BMJ

8. COZZOLINO A
   Covid-19 vaccine study pulled by US CDC is finally published.
   BMJ. 2026;394:e100157.
   

   >> Share

   
   
9. RIMMER A
   RSV vaccination programme expanded to thousands more vulnerable people.
   BMJ. 2026;394:e100171.
   

   >> Share

   
   
10. 
    Vaccination is helping to eliminate cervical cancer in several countries, and continued surveillance is essential.
    BMJ. 2026;394:e100162.
    

    >> Share

    
    

    
    Clin Infect Dis

11. ALEXANDERIAN D, Ramos F, Chatterjee S, Schwarzbold AV, et al
    Safety and Immunogenicity of the Live-Attenuated Quadrivalent Dengue Vaccine V181 Compared With Butantan-DV Among Healthy Adults in Brazil: A Randomized, Double-Blind, Phase 2 Trial.
    Clin Infect Dis. 2026 Jul 1:ciag349. doi: 10.1093.
    

    >> Share

    
    
12. DURBIN AP
    Wanted: A Relevant Correlate of Protection for Dengue Vaccines.
    Clin Infect Dis. 2026 Jul 1:ciag350. doi: 10.1093.
    

    >> Share

    
    

    
    Clin Microbiol Rev

13. PULLINGER B, Harbison-Price N, Sebina I, Na J, et al
    Current progress in developing mRNA-lipid nanoparticle vaccines against human bacterial pathogens.
    Clin Microbiol Rev. 2026 Jul 2:e0013826. doi: 10.1128/cmr.00138.
    

    >> Share

    
    

    
    J Pediatr

14. ANDERSEN KM, Ahi T, McColgan MD, Mateus JS, et al
    KP.2-Adapted BNT162b2 COVID-19 Vaccine Uptake and Effectiveness in Children.
    J Pediatr. 2026 Jul 3:115221. doi: 10.1016/j.jpeds.2026.115221.
    

    >> Share

    
    
15. MORO PL, Zauche LH, Zhang B, Dooley C, et al
    Safety of 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Children in the Vaccine Adverse Event Reporting System.
    J Pediatr. 2026 Jul 1:115213. doi: 10.1016/j.jpeds.2026.115213.
    

    >> Share

    
    

    
    J Virol

16. CALLAWAY HM
    Structural overview of lyssavirus glycoproteins, antibodies, and receptors.
    J Virol. 2026;100:e0178625.
    

    >> Share

    
    
17. VAN PUL L, Rosendahl Huber SK, Jacobi R, Hendriks M, et al
    Cross-reactive antibody and T-cell responses after influenza virus infection in community-dwelling older adults.
    J Virol. 2026 May 12:e0040726. doi: 10.1128/jvi.00407.
    

    >> Share

    
    
18. DAINES R, Sadeyen J-R, Chang P, Iqbal M, et al
    Mapping hemagglutinin residues driving antigenic diversity in H5Nx avian influenza viruses.
    J Virol. 2026 Apr 30:e0009526. doi: 10.1128/jvi.00095.
    

    >> Share

    
    

    
    Lancet

19. BLAKNEY AK, Top KA, Cowling BJ, Larson HJ, et al
    Safety and efficacy of mRNA vaccines: a mechanistic and public health perspective.
    Lancet. 2026 Jun 30:S0140-6736(26)00512-X. doi: 10.1016/S0140-6736(26)00512.
    

    >> Share

    
    

    
    PLoS One

20. WYCHRIJ DA, Rabacal W, Chapman TI, Willems HME, et al
    Immunization with the pan-fungal vaccine, NXT-2a, reduces fungal burden following serial intravaginal challenges with C. albicans in a non-human primate model of experimental vulvovaginal candidiasis.
    PLoS One. 2026;21:e0352577.
    

    >> Share

    
    
21. HARNQVIST T, Bergman K, Backhaus E, Dahl M, et al
    Epidemiology of invasive pneumococcal disease in Southwest Sweden during the first eleven years after the introduction of general childhood pneumococcal vaccination.
    PLoS One. 2026;21:e0352333.
    

    >> Share

    
    
22. WERTZ E, Babinska M, Batorski D, Louison-Lavoy D, et al
    Ad-based social media interventions increase belief accuracy and generate pro-social opinions among non-news readers.
    PLoS One. 2026;21:e0352588.
    

    >> Share

    
    
23. FELEKE HG, Simegn MB, Worede DT, Tilahun WM, et al
    Spatial distribution of uptake of newly introduced vaccines and its associated factors among children aged 12-35 months in Ethiopia: Multi-scale Geographically Weighted Regression Analysis.
    PLoS One. 2026;21:e0345899.
    

    >> Share

    
    

    
    Vaccine

24. NAKANO T, Iwata S, Oishi K, Iguchi E, et al
    Immunogenicity and safety of a SARS-CoV-2 recombinant vaccine S-268024 booster vaccination versus NVX-CoV2373: Interim results from a phase 3, multicenter, randomized, observer-blind, active-controlled study.
    Vaccine. 2026;88:128871.
    

    >> Share

    
    
25. DEPICKERE S, Pannus P, Houben S, Charles A, et al
    Safety and immunogenicity of a reduced, homologous booster dose of the BNT162b2 mRNA COVID-19 vaccine: a single blind, randomized, non-inferiority follow-up trial.
    Vaccine. 2026;89:128897.
    

    >> Share

    
    
26. MALTEZOU HC, Borg M, Botelho-Nevers E, Brantsaeter AB, et al
    Vaccination policies for healthcare personnel in Europe, 2026.
    Vaccine. 2026;88:128839.
    

    >> Share

    
    
27. BROWN J, Brennan H, Levine CB, Gwynn L, et al
    A historical overview of the anti-vaccine movement and its public health implications.
    Vaccine. 2026;89:128903.
    

    >> Share

    
    
28. PRAT-AYMERICH C, Yeghiazaryan L, Pathirana RD, Gautier V, et al
    A prematurely terminated phase 2, randomised trial to evaluate immunogenicity and reactogenicity of a single versus two-dose primary vaccination regimen of the mRNA vaccine BNT162b2 in previously SARS-CoV-2 infected children 5-11 years old (CoVacc tri
    Vaccine. 2026;88:128769.
    

    >> Share

    
    
29. GANDHI V, Kinariwala K, Kesling GL
    Under-vaccination as a systems failure: A Monte Carlo simulation of the 2025 CDC/ACIP hepatitis B birth-dose policy shift and multi-level intervention packages, 2025-2035.
    Vaccine. 2026;89:128883.
    

    >> Share

    
    
30. TORRE L, Hadler SC, Hopkins KL, Sommers T, et al
    Innovative webinar-based training to support evidence-to-recommendation decision-making by national immunization technical advisory groups: multi-country experience with hexavalent vaccines.
    Vaccine. 2026;88:128856.
    

    >> Share

    
    
31. YADEGARYNIA D, Keyvanfar A, Keyvani H, Tehrani S, et al
    Corrigendum to "Immunogenicity and safety of a quadrivalent recombinant influenza vaccine manufactured in Iran (FluGuard) in volunteers aged 18-60 years: A double-blind, non-inferiority, randomized controlled trial" [Vaccine 42(9) (2024) 2254-2259].
    Vaccine. 2026;88:128881.
    

    >> Share

    
    
32. CAMPO JJ, Pearse O, Zuza AM, Oberai A, et al
    Human systemic and mucosal immune responses support further exploration of a Klebsiella pneumoniae protein-based vaccine.
    Vaccine. 2026;89:128893.
    

    >> Share

    
    
33. TSHILUMBA SM, Ruiz PM, Matuvanga TZ, Lemey G, et al
    Protocol for a phase 3, randomized, double-blind clinical trial evaluating the safety and immunogenicity of the MVA-BN(R) vaccine against mpox in children aged 4 to less than 24 months in the Democratic Republic of the Congo: Data to guide future paed
    Vaccine. 2026;89:128890.
    

    >> Share

    
    
34. EZEJA L, Ezeala OM, Westrick SC, Qian J, et al
    Adverse events and vaccine administration errors following RSV vaccination: Findings from the United States VAERS database, 2023-2025.
    Vaccine. 2026;89:128896.
    

    >> Share

    
    
35. BARBAROUX A, Serati I, Milhabet I
    Effectiveness and acceptability of an opt-out nudge to promote influenza vaccination among medical residents: A randomized controlled trial.
    Vaccine. 2026;89:128894.
    

    >> Share

    
    
36. MORRIS SE, O'Halloran A, Sundaresan D, Olson SM, et al
    Public health benefits of maternal influenza vaccination among pregnant women and infants <6 months in the United States, 2011-2020.
    Vaccine. 2026;89:128895.
    

    >> Share

    
    
37. WHITWORTH HS, Beshir KB, Baisley KJ, Mbwanji G, et al
    Effect of malaria parasitaemia on antibody responses to single-dose and two-dose HPV vaccination: results from the DoRIS dose-reduction immunogenicity trial in Tanzanian girls.
    Vaccine. 2026;89:128889.
    

    >> Share

    
    
38. LIU STH, Gonzalez-Dominguez I, Martinez-Perez A, Bozkus CC, et al
    Phase 1 trial of intranasal NDV-HXP-S in previously vaccinated adults.
    Vaccine. 2026;89:128870.
    

    >> Share

    
    
39. ULLAH S, Parizi LF, Almutairi MM, Ali A, et al
    In silico selection and in vivo evaluation of scoloptoxin SSD14, Rm-inositol monophosphatase, and Rm-neprilysin as potential anti-tick vaccines.
    Vaccine. 2026;88:128789.
    

    >> Share

    
    
40. MYERS TR, Zauche LH, Marquez PL, McCullum I, et al
    V-safe: Summary of findings reported after COVID-19 vaccination to a US CDC active safety surveillance system through June 2023.
    Vaccine. 2026;88:128725.
    

    >> Share

    
    
41. KAUTZ A, Yang DH, Chickery S, Irving SA, et al
    Influence of correlated vaccination behaviors on estimates of COVID-19 vaccine effectiveness in older adults - VISION network, October 2023 - March 2024.
    Vaccine. 2026;89:128891.
    

    >> Share

    
    
42. HALWE NJ, Krammer F
    Vaccine strategies and development before and during the 1968 H3N2 influenza pandemic.
    Vaccine. 2026;89:128877.
    

    >> Share

    
    

    
    Virus Res

43. STUART PM, Yin ZT
    Vaccination with an HSV-1 virus containing CD-137L reduces herpetic corneal disease when used both prophylactically and therapeutically.
    Virus Res. 2026 Jun 30:199773. doi: 10.1016/j.virusres.2026.199773.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share